Skip to main content
Premium Trial:

Request an Annual Quote

QuantuMDx Raises $14M to Support Development of POC Genotyping Assay

NEW YORK – QuantuMDx said Monday that it has recently closed a $14 million financing round consisting of a mix of debt and ordinary equity.

The firm said it will use the funds, which were supported by existing shareholders, to support progress toward the commercial launch of its Q-POC high-risk HPV genotyping assay, planned for early 2021.

The Newcastle upon Tyne, UK-based company said that it has started the CE mark approval process of commissioned Q-POC devices and expects to certify them in the first half of this year.

"QuantuMDx’s Q-POC is the first true battery-operated, point-of-care molecular diagnostics device capable of performing both simple molecular tests and large syndromic and resistance mutation panels rapidly and at a price point appropriate for decentralized testing," Jonathan O’Halloran, cofounder and the new CEO of QuantuMDx, said in a statement.

The company is developing the device "to be robust for in-field testing and designed to manage dust, different ambient temperatures, humidity, and intermittent electricity," O'Halloran said.

In December, QuantuMDx and Santa Cruz, California-based Ontera announced that they are collaborating to develop technology for the detection of bloodstream infections and drug-resistance.

In November, QuantuMDx and SpeeDx announced a collaboration with the Foundation for Innovative New Diagnostics (FIND) to assess the feasibility of porting SpeeDx sexually transmitted infection tests to the QuantuMDx point-of-care testing device.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.